Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
The US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Ra2) in cancer immunotherapy.

IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. IL-13Rα2 is an important target of ImmunoCellular’s lead product candidate, ICT-107, a dendritic cell vaccine directed against glioblastoma antigens and cancer stem cells, as well as ICT-140, a dendritic cell vaccine to treat ovarian cancer.

“We believe that this issued patent will complement and extend the broad intellectual property protection we have established for two of our company’s key assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “IL-13Rα2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach.”

The IL-13Rα2 patent was issued to The Penn State Research Foundation, the technology transfer agent for The Pennsylvania State University, and is licensed to Targepeutics, Inc. ImmunoCellular is a sub-licensee of the patent.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
Key patent application covers ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.
Tuesday, March 05, 2013
ImmunoCellular Therapeutics’ Investigational New Drug Application for ICT-140 Allowed by the FDA
Investigational new drug (IND) application for ICT-140 paves the way for conducting a clinical trial.
Wednesday, January 30, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Immunotherapy Technique Holds Promise for Curing Food Allergies
Scientists develop immunotherapy technique that almost eliminating allergic response and anaphylactic response in food-allergic mice.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Skin patch to treat peanut allergy shows benefit in children
NIH-funded study suggests patch is safe, convenient mode of treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos